Skip to content

Rituximab versus tocilizumab in anti-TNF inadequate responders: R4RA

One-paragraph summary

R4RA randomized 164 anti-TNF inadequate responders to rituximab or tocilizumab within a multicenter synovial-biopsy framework. The study tested whether low/absent synovial B-cell biology predicted lower response to B-cell depletion than IL-6 receptor blockade. Histologic and RNA-based classifiers did not behave identically; the molecular B-cell signature was more informative in analyses (PMID 33485455; companion biomarker analysis PMID 35589854).

Key findings

  • Tissue sampling was feasible in a multicenter randomized trial.
  • Many RA synovia had low/absent B-cell signatures despite systemic diagnosis.
  • Molecular and histologic definitions of B-cell-poor disease differed.
  • The study demonstrated a path to biomarker-by-treatment interaction testing.

Limitations

  • It did not yield a simple routine companion diagnostic.
  • One sampled joint may not represent all joints or later time points.
  • Assay speed, thresholding, cost and external replication remain barriers.

Why it matters

R4RA moved RA precision medicine from retrospective responder signatures into prospective target-tissue randomization.

Cited by wiki pages

  • overview
  • synovial immunobiology
  • biomarkers and tissue precision
  • clinical trials landscape